Clinical laboratory billing PAMA obligations sit in an odd place. The reporting requirement is federal, the payment consequences are large, and yet the rules have been rewritten by Congress so many times that most labs have stopped tracking where things actually stand.
That uncertainty has a cost. Labs plan budgets around rates that may drop, teams prepare for reporting windows that move, and the daily coding work that decides most lab revenue gets less attention than the legislative drama. Both parts matter, and the second one is the part a lab controls.
What PAMA Changed About Lab Payment
The Protecting Access to Medicare Act of 2014 rebuilt the Clinical Laboratory Fee Schedule around private market data. Instead of setting rates administratively, Medicare now pays most clinical diagnostic laboratory tests based on the volume weighted median of private payer rates that laboratories report.
The design assumed broad reporting. The first collection captured a small share of laboratories, weighted toward large commercial labs, while excluding most hospital outreach labs and undersampling physician office labs. Rates came in lower than the market they were meant to reflect, which produced several consecutive years of reductions and a running argument that has not been settled since.
Where PAMA Reporting Stands Right Now
The Consolidated Appropriations Act of 2026, signed February 3, 2026, changed three things at once, and a lab working from older guidance will have the timing wrong.
The Reporting Window Has Closed
The data reporting period ran May 1 through July 31, 2026. It replaced a window that had been scheduled for earlier in the year, and it is now behind us.
The data reported covered private payer rates from January 1 through June 30, 2025. That collection period is itself a change, since the previously scheduled reporting would have used 2019 data to set rates in a market that had moved considerably since then.
What Happens to Rates
There is no phase-in reduction during 2026. Beginning January 1, 2027 and running through 2029, payment for a test may not be reduced by more than fifteen percent per year compared to the prior year’s rate.
What labs submitted this summer sets the Clinical Laboratory Fee Schedule rates effective January 1, 2027. Labs that reported should be modeling what those rates do to their payer mix now rather than reacting in January. Labs that concluded they were not an applicable laboratory should have that determination documented, because the analysis is the record if the question comes up later.
Who Counts as an Applicable Laboratory
The threshold test trips up hospital outreach programs in particular. A hospital-based outreach laboratory qualifies when it furnishes tests to nonpatients rather than admitted inpatients or registered outpatients, bills Medicare Part B for those nonpatient services under the appropriate bill type, and meets the low expenditure threshold during the collection period.
The determination is made at the level of the entity that bills, not the hospital as a whole, which is why organizations sometimes conclude they are exempt when one of their units is not.
Panels, Components & Bundling
The reporting fight gets the attention, and panel logic quietly decides more day to day revenue.
Automated Panels Have to Be Billed as Panels
When every component of an organ or disease oriented panel is performed, the panel code is what gets reported. Billing the components separately produces a higher charge and a denial, and repeated across a high volume lab it becomes the kind of pattern that draws review rather than a coding disagreement.
The reverse error costs money quietly. When a panel is ordered but only part of it is performed, the individual component codes are correct, and labs that default to the panel code in every case are underbilling on those encounters.
Edits Do Not Excuse the Underlying Rule
Claim edits catch some component billing and not all of it. A claim that passes an edit is not confirmation that the coding was right. Billing teams that handle high lab volume, including specialty firms like AAA Medical Billing, generally build panel logic into charge entry rules rather than relying on the clearinghouse to catch it downstream, because by the time an edit fires the pattern has usually been running for months.
Modifiers That Carry Weight
A handful of modifiers do most of the work in lab billing, and misuse of them is a common audit finding.
Modifier 91 reports a repeat clinical diagnostic laboratory test on the same day when repeated testing is needed to obtain subsequent results. It does not apply to reruns caused by equipment problems, specimen issues, or confirmation of an initial result. That distinction is the one auditors check.
Modifier 90 identifies a test referred to an outside laboratory. Modifier QW identifies tests performed under a CLIA waived certificate, and claims for waived tests submitted without it are denied on codes that require it. The professional and technical split, reported with modifiers 26 and TC, governs pathology work and depends on who owns the equipment and who performs the interpretation.
Pathology Adds Its Own Counting Problem
Surgical pathology codes are reported per specimen, and the definition of a specimen is where money is won and lost. Separately identified and separately submitted tissue generally supports separate units. Multiple blocks from a single specimen generally do not.
Under-reporting units on multi-specimen cases is common in practices that grew quickly, and it does not generate a denial. The claim pays, just for less than the work supported.
Medical Necessity & Advance Notice
Several national coverage determinations govern specific laboratory tests, and each carries its own diagnosis requirements. Orders need to be traceable to a treating physician, and standing orders without periodic review are a recurring finding in audits of high volume labs.
When a test is likely to be denied as not reasonable and necessary, the advance beneficiary notice has to be issued before the service and signed, with the appropriate modifier on the claim. Issuing it afterward does not preserve the ability to bill the patient.
What Labs Should Be Doing Now
The reporting cycle is done, so attention belongs on the rate impact and the daily coding work.
Model the 2027 rates against your test mix once CMS publishes them, since a fifteen percent annual limit still compounds across three years. Audit panel and component billing against actual performed tests rather than orders. Review modifier 91 use specifically, since it is the one most often applied to situations it does not cover. Confirm that pathology unit counting matches specimen submission.
Rate policy will keep moving, and Congress has intervened repeatedly enough that another change is reasonable to expect. The coding accuracy underneath it is the part that pays the same regardless of what happens in Washington.